Sep. 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Sep 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.
Merck Updates Phase 3 KEYFORM-007 Trial on Experimental Fixed-Dose Favezelimab and Pembrolizumab Combo for PD-L1 Positive Metastatic Colorectal Cancer Post-Treatment.
Recent data reveal that Almirall’s EBGLYSS® (Lebrikizumab) maintained long-term disease control for up to three years in over 80% of adults and adolescents with moderate-to-severe atopic dermatitis.